Metoprolol Succinate
Product Images NDC 62207-143

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 62207-143). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Granules India Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Meto-100mg-30s.jpg (Meto 100mg 30s)

Label for Metoprolol Succinate Extended-Release Tablets, USP 100 mg, manufactured by Granules India Limited. The label states the package contains 30 tablets and includes dosage strength, storage instructions, and warnings. It features the NDC code 62207-142-54 and notes that the product is Rx only and made in India.*

FDA Label Image

Meto-200mg-30s.jpg (Meto 200mg 30s)

Metoprolol Succinate Extended-Release Tablets USP 200 mg, bottle label showing 30 tablets. Manufactured by Granules India Limited, made in India, and manufactured for Granules Pharmaceuticals Inc. Dosage and storage instructions included. NDC 62207-143-54.*

FDA Label Image

Meto-25mg-30s.jpg (Meto 25mg 30s)

Label for Metoprolol Succinate Extended-Release Tablets, USP 25 mg, showing a 30 tablets count. It includes dosage strength, storage instructions, manufacturer Granules India Limited, and manufactured for Granules Pharmaceuticals Inc. The label also features NDC 62207-140-54 and a barcode.*

FDA Label Image

Meto-50mg-30s.jpg (Meto 50mg 30s)

Metoprolol Succinate Extended-Release Tablets, USP 50 mg label showing NDC 62207-141-54, bottle containing 30 tablets. The label states each tablet contains 47.5 mg metoprolol succinate equivalent to 50 mg metoprolol tartrate. Manufactured by Granules India Limited in Hyderabad, India, and labeled for Granules Pharmaceuticals Inc., Chantilly, VA. Storage instructions and barcode are visible.*

FDA Label Image

Meto-figure.jpg (Meto Figure)

A forest plot chart titled "Results for Subgroups in MERIT-HF" showing relative risk and 95% confidence intervals for subgroups related to total mortality, total mortality or all-cause hospitalization, and total mortality or hospitalization for heart failure. Subgroups include geographic location, NYHA class, ejection fraction, ischemic etiology, sex, race, prior myocardial infarction status, diabetes status, hypertension history, and heart rate. The chart compares outcomes favoring metoprolol succinate extended-release tablets versus placebo.*

FDA Label Image

Meto-structure.jpg (Meto Structure)

Chemical structure diagram of Metoprolol Succinate showing the molecular arrangement of its active ingredient components, including the succinate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.